PLA2G4A Antibodies

Cytosolic phospholipase A2 (PLA2G4A)

Selectively hydrolyzes arachidonyl phospholipids in the sn-2 place releasing arachidonic acid. Together with its lysophospholipid action, it is implicated in the initiation of the inflammatory reaction.

.

Gene Information

Human
Gene Name:	PLA2G4A
Uniprot:	P47712
Entrez:	5321

Family

Belongs to:
No superfamily

Alternative Names

calcium-dependent phospholipid-binding protein; cPLA2; cPLA2-alpha; lysophospholipase; MGC126350; phosphatidylcholine 2-acylhydrolase; Phospholipase A2 group IVA; phospholipase A2, group IVA (cytosolic, calcium-dependent); PLA2G4A; PLA2G4cytosolic phospholipase A2

Molecular Weight

Mass (kDA):
85.239 kDA

Genomic Context

Human
Location:	1q31.1
Sequence:	1; NC_000001.11 (186828949..186988981)

Tissue Specificity

Expressed in various tissues such as macrophages, platelets, neutrophils, fibroblasts and lung endothelium.

Subcellular Localizations

Cytoplasm. Cytoplasmic vesicle. Translocates to membrane vesicles in a calcium-dependent fashion.

Diseases

• Inflammation
• Schizophrenia
• Malignant Neoplasms
• Dysequilibrium Syndrome
• Asthma
• Endometrial Polyp
• Edema
• Neoplasms
• Arthritis
• Infarction
• Inflammatory Response
• Fibrosis

• Diabetes Mellitus
• Degenerative Polyarthritis
• Pneumonia
• Pathologic Vasoconstriction
• Hypertrophy
• Cardiovascular Diseases
• Myocardial Infarction

Pathways

• Secretion
• Pathogenesis
• Localization
• Embryo Implantation
• Parturition
• Inflammatory Response
• Fertilization
• Immune Response
• Reverse Transcription
• Cell Proliferation
• Ovulation
• Transport
• Apoptotic Cell Clearance

• Cell Activation
• Cell Migration
• Regulation Of Signaling
• Monocyte Chemotaxis
• Neutrophil Extravasation
• Fibroblast Proliferation
• Mitochondrial Depolarization

PTMs

• Phosphorylation

• Oxidation

• Cleavage

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/PLA2G4A

Best Uses Of The PLA2G4A Marker From Boster Bio

This article will discuss Boster Bio's Anti-Phospholipase 2/PLA2G4A marker application as well as validation and references. Like all products, Boster Bio will offer an unrestricted sample of its antibody to help you decide which one is best for you. If you have any concerns, please be sure to contact us.

Boster Bio Anti-Phospholipase A2/PLA2G4A Marker

Designed for use in biomedical research, Boster Bio Anti-Phospholipolipase A2/PLA2A Marker is a monoclonal antibody for the detection of PLA2G4A. It includes a mouse-specific monoclonal antibodies with a goat-specific biotinylated polyclonal antibody. When the sample is added unbound conjugates are flushed away using PBS or TBS buffer. Then an enzymatic reaction takes place between HRP and TMB occurs.

Applications

PLA2G4A encodes a calcium-dependent cell-surface phospholipase, which releases PUFAs from cellular cells. This gene also enhances endothelial cells ' expression of intracellular adhesion molecules 1, which is a well-known mediator for monocyte recruitment to the artery walls. The PLA2G4A gene is highly expressed, yet its expression is lower than its wild-type counterpart. Nevertheless, it is an extremely useful indicator for assessing the risk of cardiovascular illness in individuals.

Anti-PLA2G4A antibodies can be used to detect this protein. The Anti-PLA2G4A antibody has been tested for use in immunohistochemistry, immunocytochemistry, and western blot. This antibody is produced against the PLA2G4A antigen . It has been successfully used in these applications. The dilutions must be adjusted to suit the specific needs of your lab, however the general protocol can be found at GeneTex the website.

Validation

Validation of the Boster Bio PLA2A marker was done using lncRNA-based probes developed by TSINGKE Biological Technology in Beijing, China. The samples were incubated at 37°C overnight and then visualized using commercial ISH kit (BCIP/NBT), from Boster Bio, USA. The presence of an ISH signal is indicated by the blue staining. Two independent physicians rated the ISH signals in a blind way to clinical features and diagnoses.

Refer to

The expression of the PLA2G4A gene may have therapeutic or prognostic implications. It may have particular significance for a subtype with elevated HOXA9 and MEIS1 levels. This marker isn't directly involved in the treatment or prevention of cancer. It remains an intriguing marker for the moment. Here are some references to the marker PLA2G4A.

PLA2 hydrolyzes the phospholipids. This activity results in a reduction of PC/ePC36:3 molecular species. Similar reductions in self-renewal frequency could be achieved through the inhibition of this protein. PLA2 may play an important role in the treatment of H9M-dependent AML using MLL rearrangement. These results suggest that PLA2G4A could be a therapeutic target.

In contrast, the PLA2G4A gene expression levels in healthy and malignant hematopoiesis are different. PLA2G4A expression was highest in AML with the t(11q23/MLL) mutation and was lower in healthy hemopoiesis. Progenitors also expressed PLA2G4A at comparable levels as HSC. PLA2G4A expression was also higher in the pediatric patients with MLL fusions.